Completed
NCT Number: NCT01237288
Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets
The purpose of this study is to investigate the efficacy and safety of oral phosphate (Z-521) in subjects with primary hypophosphatemic rickets.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
1 year–14 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Chiba Children's Hospital, Chiba, Japan
Loading trial locations.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Diagnosed as primary hypophosphatemic rickets based on familial history, genetic test or laboratory test results.
Exclusion criteria
- A hyperparathyroidism
Treatment and study plan
Primary outcomes
-
Serum ALP level
Time frame: 6 month
-
Serum phosphate level
Time frame: 6 month
Sponsors and collaborators
Lead sponsor
Zeria Pharmaceutical
Industry
Registry information
Important dates
- Study start
- 2010
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- Nov 9, 2010
- Registry last updated
- Oct 1, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.